Brief: Silence Therapeutics Announces FDA Fast Track Designation For Sln124, A Novel Investigational Sirna Therapy For The Treatment Of Polycythemia Vera

Silence Therapeutics

08/09/2022 13:36

Sept 8 (Reuters) - Silence Therapeutics PLC  SLNCF.PK :
    * SILENCE THERAPEUTICS ANNOUNCES FDA FAST TRACK DESIGNATION
FOR
SLN124, A NOVEL INVESTIGATIONAL SIRNA THERAPY FOR THE TREATMENT
OF POLYCYTHEMIA VERA
    * SILENCE THERAPEUTICS PLC - PLANS TO START A PHASE 1/2
STUDY IN
PV PATIENTS THIS YEAR

Source text for Eikon:  ID:nBw4gCn4ya 
Further company coverage:  SLNCF.PK 

 (Reporting by Pratik Jain)
 ((Pratik.Jain@thomsonreuters.com;))